NCT04521348View on ClinicalTrials.gov

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Thyroid Cancer

Interventions

DRUG

multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody

Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT04521348 - Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer | Biotech Hunter | Biotech Hunter